O

Optomed Oyj
OMXH:OPTOMED

Watchlist Manager
Optomed Oyj
OMXH:OPTOMED
Watchlist
Price: 4.2 EUR 0.84% Market Closed
Market Cap: 81m EUR
Have any thoughts about
Optomed Oyj?
Write Note

Optomed Oyj
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Optomed Oyj
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
O
Optomed Oyj
OMXH:OPTOMED
Research & Development
-€230k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
R
Revenio Group Oyj
OMXH:REG1V
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Modulight Oyj
OMXH:MODU
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bioretec Oy
OMXH:BRETEC
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
N
Nexstim Oyj
OMXH:NXTMH
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Biohit Oyj
OMXH:BIOBV
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Optomed Oyj
Glance View

Market Cap
82.3m EUR
Industry
Health Care

Optomed Oyj engages in the provision of handheld fundus cameras and eye-screening solutions. The company is headquartered in Oulu, Oulun and currently employs 115 full-time employees. The company went IPO on 2019-12-09. The Group's Parent Company, Optomed Oyj, is responsible for, among other things, the management of the Group as well as finance and accounting functions, human resources, legal affairs and corporate communication. The Group's business is managed through two reportable segments: Devices and Software. The Devices segment develops, commercializes and manufactures easy-to-use and affordable handheld fundus cameras. The Software segment develops and sells screening software for diabetic retinopathy and cancer screening for healthcare organizations. The Optomed Group consists of the parent company Optomed Oyj and four subsidiaries in Finland, China, the USA and Hong Kong.

OPTOMED Intrinsic Value
3.49 EUR
Overvaluation 17%
Intrinsic Value
Price
O

See Also

What is Optomed Oyj's Research & Development?
Research & Development
-230k EUR

Based on the financial report for Dec 31, 2023, Optomed Oyj's Research & Development amounts to -230k EUR.

What is Optomed Oyj's Research & Development growth rate?
Research & Development CAGR 1Y
36%

Over the last year, the Research & Development growth was 36%.

Back to Top